Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSEN1 | P49768 | 10/20 | 0.38 |
| ▸ | PSEN2 | P49810 | 10/20 | 0.38 |
| ▸ | APH1B | Q8WW43 | 10/20 | 0.38 |
| ▸ | NCSTN | Q92542 | 10/20 | 0.38 |
| ▸ | APH1A | Q96BI3 | 10/20 | 0.38 |
| ▸ | PSENEN | Q9NZ42 | 10/20 | 0.38 |
| ▸ | APP | P05067 | 4/20 | 0.37 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18952715 | 1.00 | PSEN1 (0.38) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL18971166 | 1.00 | PSEN1 (0.38) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL21050393 | 1.00 | PSEN1 (0.38) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL18971164 | 1.00 | PSEN1 (0.38) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL20159585 | 0.90 | PSEN1 (0.34) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL23504794 | 0.78 | RIPK1 (0.32) | RIPK1 | |
| SCHEMBL21050359 | 0.75 | PSEN1 (0.43) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL21050361 | 0.75 | PSEN1 (0.43) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL21050360 | 0.75 | PSEN1 (0.43) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL18952771 | 0.75 | PSEN1 (0.43) | PSEN1PSEN2APH1BNCSTNAPH1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11319314-B2 | Phenoxytriazoles | HOFFMANN-LA ROCHE INC. (US) | 2022-05-03 | — | — | US | disclosed |
| US-20210309653-A1 | PHENOXYTRIAZOLES | HOFFMANN-LA ROCHE INC. (US) | 2021-10-07 | — | — | US | disclosed |
| EP-3538516-B1 | PHENOXYTRIAZOLES | HOFFMANN LA ROCHE (CH) | 2021-06-16 | — | — | EP | disclosed |
| EP-3484884-B1 | FUSED PYRIMIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2021-01-27 | — | — | EP | disclosed |
| EP-3386978-B1 | BRIDGED PIPERIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2021-01-27 | — | — | EP | disclosed |
| US-10875854-B2 | Triazolopyridines | HOFFMANN-LA ROCHE INC. (US) | 2020-12-29 | — | — | US | disclosed |
| US-20200291034-A1 | BRIDGED PIPERIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2020-09-17 | — | — | US | disclosed |
| US-20200291034-A1 | BRIDGED PIPERIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2020-09-17 | — | — | US | disclosed |
| US-10730881-B2 | Fused pyrimidine derivatives | HOFFMANN-LA ROCHE, INC. (US) | 2020-08-04 | — | — | US | disclosed |
| US-10730881-B2 | Fused pyrimidine derivatives | HOFFMANN-LA ROCHE, INC. (US) | 2020-08-04 | — | — | US | disclosed |
| US-10562903-B2 | Bridged piperidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2020-02-18 | — | — | US | disclosed |
| US-10562903-B2 | Bridged piperidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2020-02-18 | — | — | US | disclosed |
| US-20190194183-A1 | TRIAZOLOPYRIDINES | HOFFMANN-LA ROCHE INC. (US) | 2019-06-27 | — | — | US | disclosed |
| US-20190177329-A1 | FUSED PYRIMIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2019-06-13 | — | — | US | disclosed |
| US-20190177329-A1 | FUSED PYRIMIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2019-06-13 | — | — | US | disclosed |
| US-20190010156-A1 | BRIDGED PIPERIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2019-01-10 | — | — | US | disclosed |
| EP-3386978-A1 | BRIDGED PIPERIDINE DERIVATIVES | H. Hoffnabb-La Roche Ag (CH) | 2018-10-17 | — | — | EP | disclosed |
| WO-2017097728-A1 | BRIDGED PIPERIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2017-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210309653-A1 | PHENOXYTRIAZOLES | HTT, PSEN1, APP | PSEN1 2/4885PSEN2 7/4885APH1B 30/4885 |
| US-10730881-B2 | Fused pyrimidine derivatives | APP, UPF1, PSEN1 | PSEN1 3/4885PSEN2 10/4885APH1B 23/4885 |
| US-20190194183-A1 | TRIAZOLOPYRIDINES | HTR2A, APP, PTGDR | PSEN1 14/4885PSEN2 32/4885APH1B 53/4885 |
| US-20200291034-A1 | BRIDGED PIPERIDINE DERIVATIVES | PTGDR, HPGDS, PSEN1 | PSEN1 3/4885PSEN2 21/4885APH1B 30/4885 |
| US-20190177329-A1 | FUSED PYRIMIDINE DERIVATIVES | APP, UPF1, PSEN1 | PSEN1 3/4885PSEN2 10/4885APH1B 23/4885 |
| US-10562903-B2 | Bridged piperidine derivatives | PTGDR, HPGDS, PSEN1 | PSEN1 3/4885PSEN2 21/4885APH1B 30/4885 |
| US-20190010156-A1 | BRIDGED PIPERIDINE DERIVATIVES | PTGDR, HPGDS, PSEN1 | PSEN1 3/4885PSEN2 21/4885APH1B 30/4885 |
| US-11319314-B2 | Phenoxytriazoles | HTT, APP, PSEN1 | PSEN1 3/4885PSEN2 11/4885APH1B 37/4885 |
| US-10875854-B2 | Triazolopyridines | HTR2A, APP, PTGDR | PSEN1 14/4885PSEN2 32/4885APH1B 53/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.